Search

everythinglearnresearchcommunity

for

Search:↓

A user shared their 6.5-month experience with topical finasteride (2%) and minoxidil (5%), noting initial progress followed by a significant shedding phase. Others in the conversation reassured that shedding is normal and suggested staying consistent with the treatment for potential regrowth.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

PP405 is a potential hair loss treatment that may reactivate dormant hair follicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.

The user discovered they had been using fake minoxidil for almost two years, which stopped working, and switched to finasteride, which slowed hair loss. They recently started using real minoxidil and noticed a shedding phase, indicating it might be effective.

The user experienced significant hair improvement using topical Minoxidil and oral Finasteride, despite an initial shedding phase. They prefer oral Finasteride for convenience and are considering oral Minoxidil, while others in the conversation discuss potential side effects and personal experiences with these treatments.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

A user discusses using latanoprost, a costly treatment that may extend the hair growth phase and improve hair quality, wondering why it's not more popular. They already use a combination of finasteride and minoxidil and plan to incorporate latanoprost into their routine.

A 25-year-old experienced significant hair regrowth using 5% minoxidil for 9.5 months despite an initial shed and a second shedding phase lasting 3.5 months. They encourage others to persist with minoxidil treatment through shedding as regrowth can occur.

Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.

Pyrilutamide, a potential hair loss treatment that has been tested in Phase 2 trials and may be available for purchase through a group buy in June. It is purported to have similar effects on hair growth as Dutasteride.

The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.

The user experienced significant hair improvement using finasteride, minoxidil, ketoconazole shampoo, and microneedling over a year, with no side effects. They used topical minoxidil and reported shedding phases, but no current shedding as of March 2026.

The user shared their hair loss treatment progress using Finasteride, Dutasteride, and Minoxidil, noting initial irritation with topical Minoxidil and experiencing shedding phases. They reported no side effects and encouraged others to try this regimen for alopecia.

Switching from topical to oral minoxidil and dutasteride led to severe hair thinning and shedding, with no side effects. The user is unsure if this is a temporary shedding phase or if oral minoxidil is less effective.

The conversation discusses hair shedding experienced by users on minoxidil and finasteride treatments, with some considering additional options like spironolactone and dutasteride. Many users report experiencing a second shedding phase but are advised to continue treatment as it may lead to thicker hair regrowth.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

A 28-year-old male is experiencing temple regrowth but crown thinning while using 5mg minoxidil and 0.5mg dutasteride. The shedding phase is seen as a positive sign of treatment effectiveness, with expectations of noticeable improvements around 6 to 12 months.

OP used 0.4 mg Dutasteride and 2 mg Minoxidil for 7 months, seeing significant hair density improvement without a noticeable shedding phase. OP takes a combined oral pill from Musely and is in their early forties.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

The conversation discusses hair loss treatments, specifically the transition from topical to oral minoxidil and finasteride, and the associated shedding phase. Users advise patience and consistency, noting that shedding is common and improvement may take several months.

Clascoterone 5% and PP405 are being discussed as potential future treatments for hair loss, with clascoterone nearing phase three completion and PP405 possibly taking a cosmetic route to market. Current treatments like minoxidil, finasteride, and RU58841 are mentioned as effective in slowing hair loss, but a complete cure remains elusive.

A user experienced no visible improvement in hair loss after 10 months on 0.5mg finasteride and increased the dose to 1mg, noticing a possible shedding phase. They also use topical minoxidil, ketoconazole shampoo, and dermastamping, and are seeking others' experiences with similar treatments.

A user successfully regrew hair using 1mg finasteride, switching to 0.5mg dutasteride, and maintaining 5mg oral minoxidil, with significant improvements noted after switching to dutasteride. The user experienced shedding phases but ultimately achieved regrowth and is now comfortable without wearing a hat.

A 19-year-old is experiencing crown thinning after three months on finasteride and minoxidil, hoping it's just a shedding phase. They also use a dermaroller weekly and seek hair regrowth and stabilization.

The user has been using finasteride for 16 months, minoxidil for 11 months, and started microneedling 2 months ago, experiencing shedding phases. They are questioning whether they are experiencing miniaturization or regrowth.

An 18-year-old male using minoxidil and finasteride is experiencing increased hair loss, possibly due to a shedding phase from finasteride. He also takes zinc, magnesium, calcium, and vitamin C, and is concerned about hair loss from his temples.